Search
Cardiovascular renal and metabolic diseases infographic
Our_Inflammatory_Disease_Research.pdf
CardioMetabolic_diseases.pdf
Cardiometabolic_Diseases.pdf
Central_Nervous_System_Diseases.pdf
stargardt_disease_infographic.pdf
Partnering in Infectious Diseases MAY 2024 CORP_0.pdf
Chronic Obstructive Pulmonary Disease
Partnering in Cardiometabolic Diseases MAY 2023 Corp
Partnering in CNS Diseases MAY 2024 CORP_0.pdf
Partnering in Cardiometabolic Diseases MAY 2024 CORP_0.pdf
Cardiovascular Disease
The Global Cardiovascular Disease Burden.pdf
The Global Cardiovascular Disease Burden.pdf
Kidney_Disease_in_Type_2_Diabetes.pdf
BI increases commitments to sustainable development
At the World Health Summit 2021, Boehringer Ingelheim announces updates to its strategic approach to sustainable development
Advances in vectored vaccines for poultry
Vaccine design technologies have made huge advances in recent years. One of the newer categories of vaccine, vectored vaccines, is overcoming challenges that conventional vaccines do not meet.
Spotlight on GPP
Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, answers some frequently asked questions about GPP.
Questions and Answers
Answers to common questions from both patients and health care professionals regarding Compassionate Use of experimental medications.
IPF why wait?
IPF is a progressive and life threatening lung disease that can cause permanent damage in the lungs right from the start. Early diagnosis and treatment of IPF is critical, because acting quickly can make a difference.
It’s Your Heart. Protect It. The Podcast.
In season 2, we hear from a range of experts to explore further how the interconnected systems call for collaboration and approach to care.
Bridging the gap in Generalized Pustular Psoriasis (GPP)
Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, discusses published insights from GPP patients.
Facing Pulmonary Fibrosis
Steve Jones talks about his experience facing his pulmonary fibrosis diagnosis.
Boehringer Ingelheim half-year results 2023
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas